Phase 3 Interstitial Lung Disease Trial, Recruiting NCT06716606 Sponsor: GlaxoSmithKline Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Phase 3 Interstitial Lung Disease Trial, Recruiting

NCT06716606
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have already completed a previous related trial (study 218224 or 221672) up to and including the Week 52 visit, without being considered a "treatment failure."
  • If you have the skin condition SSc, you must have an area of skin on your abdomen or upper thigh that is unaffected or only mildly affected, so that an injection under the skin can be given there.
  • You must be able and willing to give yourself the study medication by injection, or have a caregiver or healthcare professional who can do this for you throughout the trial.
  • If you are a woman who could become pregnant, you must not currently be pregnant or breastfeeding, and you must use a highly effective form of contraception (less than 1% failure rate) during the trial and for at least 4 months after your last dose.
  • If you are a woman who could become pregnant, you must have a negative pregnancy test within 24 hours before your first dose of the study medication.
  • You must be willing and able to give your informed consent, meaning you understand and agree to follow all the trial's requirements.

Who may not be able to join:

  • If you stopped taking the study medication before the Week 52 visit in the previous related trial, you would not be eligible.
  • If you have developed a significant, unstable, or uncontrolled serious illness unrelated to your underlying condition (such as heart, lung, blood, digestive, liver, kidney, nerve, cancer, or infection problems) that could put you at unnecessary risk, you may not be eligible.
  • If you have developed any other medical conditions, abnormal lab results, or other issues (such as poor vein access) that could affect how the medication works in your body, make it unsafe for you to continue, or make it hard to interpret the trial results, you may not be eligible.
  • If you have been exposed to more than a certain level of radiation (above 10 millisieverts over background) in the past 3 years — through work or previous research studies — you may not be eligible.
  • If a specific heart rhythm measurement (called the QTc interval) taken at your Week 52 visit in the previous trial was above a certain level (480 milliseconds), you may not be eligible (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: GSK Clinical Trials, GlaxoSmithKline

Phone: 877-379-3718

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
12 December 2024
Est. completion
27 December 2029

Where this trial is recruiting

🇦🇷 Argentina 🇨🇳 China 🇬🇷 Greece 🇯🇵 Japan 🇰🇷 South Korea 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Number of participants with Adverse events (AEs), Adverse Event of Special Interest events (AESIs), and Serious Adverse Event (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov